drugset / Trial / NCT00477581

A Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes Mellitus

NCT00477581

Phase 4 Completed 102 enrolled AstraZeneca Eli Lilly and Company · collab
RandomizedCrossoverTriple-blindTreatment

Summary

This purpose of this study is to compare the effect of exenatide to that of sitagliptin on 2-hour postprandial glucose in subjects with type 2 diabetes mellitus.

Timeline

Start
2007-05
Primary completion
2007-09
Completion
2007-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Exenatide Peptide 10 ug Subcutaneous
Subject Sitagliptin Small molecule 100 mg Oral